Weight Loss Drug Ads: Good or Bad?

From our archives, a favourite...Occasionally, an old advertising campaign is brought back from the dead.Even if it has been off the air for decades.In this episode, we’ll discuss a recurring Coke commercial that has been called the most popular ad of all time.A much-loved beer c ...  Show more

Because Terry LOVES books, we do an annual Bookmarks episode. This one is from 2024.There’s never enough room to include all the great stories we find in our research books.So this episode is dedicated to all those stories that didn’t fit into our regular episodes. The theme is “ ...  Show more

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Show more

$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big- ...  Show more

Yes, drugs like Ozempic, Wegovy, and Mounjaro can help people lose weight, but at what cost? Dr. Sanjay Gupta explores why these drugs may not be the right fit for everyone. Learn more about your ad choices. Visit podcastchoices.com/adchoices 

Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices